Document is current

Article History

Received: 25 August 2022

Accepted: 19 December 2022

First Online: 9 January 2023

Declarations

:

: The Swiss <i>MANagement Of Systemic Sclerosis (MANOSS)</i> cross-sectional study was reviewed and approved by the responsible Swiss ethics committee in September 2018 (EKNZ 2018‐01206). Patient information forms and informed consent documents complied with the Swiss ethics committee’s templates. All participants received a written explanation of the purpose of the study, the voluntary nature of their participation and the use of their contributions.

: Not applicable.

: AK has a consultancy relationship with and/or has received research funding from Boehringer Ingelheim, Pfizer, Swiss Nursing Science Foundation, Swiss League Against Rheumatism, and University of Basel. She is an unpaid member of the EULAR recommendations for non-pharmacological management of autoimmune connective tissue diseases task force. AAD is an Associate Professor of Nursing at Boston College whose research focuses on developing more person-centered approaches to care. He receives funding from Boston College and the U.S. National Institutes of Health (U.S.A.) and receives funding to cover travel expenses for his faculty participation in a Swiss rare diseases summer school. Dr. Dwyer has no competing interests to declare. OD has/had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Janssen, Kymera, Lupin, Medscape, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Redxpharna, Roivant, Sanofi and Topadur. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). Research Grants: Kymera, Mitsubishi Tanabe. MS, CB, JB, PKH, PM, DD, UAW, and DN declare they have no financial and non-financial interests that are directly or indirectly related to this work.